Mainstream

Exelixis Falls 8% On Abstract For Colorectal Cancer Candidate Zanzalintinib

Exelixis falls 8% on abstract for colorectal cancer candidate zanzalintinib

Exelixis falls 8% on abstract for colorectal cancer candidate zanzalintinib

Post Contentexel, rhhbyRead More

You might also be interested in reading MicroStrategy stock set to gain 30% if BTC hits $150K in 2025 — Analyst.

January 22, 2025
In Mainstream